{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"ipamorelin","urls":{"read":"https://miscsubjects.com/api/articles/ipamorelin/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/ipamorelin/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/ipamorelin/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/ipamorelin/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/ipamorelin/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/ipamorelin/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/ipamorelin/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"ipamorelin","title":"ipamorelin","register":"standard","tags":[],"updated_at":"2026-07-17T02:39:46.410Z","body_excerpt":"## Overview\nEvidence is being populated by Grok web search.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"2024 animal study showing ipamorelin (and anamorelin) reduces cisplatin-induced weight loss in ferrets during delayed phase when given intraperitoneally, with no effect on emesis itself.","tier":"preclinical","weight":0.5,"section":"mechanism","slot":"mechanism","interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c2","text":"2026 narrative review discussing ipamorelin among unapproved peptides, noting animal model benefits but scarce human safety data and regulatory concerns for sports medicine use.","tier":"preclinical","weight":0.5,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39043357/","title":"The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism","quote":"This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. ... Neither of compounds administered i.p. had any effect on cisplatin-induced acute or delayed emesis, but both inhibited associated cisplatin-induced weight loss on the last day of delayed phase (48-72 h) by approximately 24 %.","summary":"2024 animal study showing ipamorelin (and anamorelin) reduces cisplatin-induced weight loss in ferrets during delayed phase when given intraperitoneally, with no effect on emesis itself.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"ef254b1d435558a6eaafff72433f7900452d14922ec9596f292a34df8daced67"},{"id":"s2","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41966639/","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","quote":"Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 ... ipamorelin, MOTS-C ... Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients.","summary":"2026 narrative review discussing ipamorelin among unapproved peptides, noting animal model benefits but scarce human safety data and regulatory concerns for sports medicine use.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"50f46187c788165037bbb94993c92d84e776164cc64d8a86d02b1c39d3264174"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39043357/","title":"The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism","quote":"This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. ... Neither of compounds administered i.p. had any effect on cisplatin-induced acute or delayed emesis, but both inhibited associated cisplatin-induced weight loss on the last day of delayed phase (48-72 h) by approximately 24 %.","summary":"2024 animal study showing ipamorelin (and anamorelin) reduces cisplatin-induced weight loss in ferrets during delayed phase when given intraperitoneally, with no effect on emesis itself.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"ef254b1d435558a6eaafff72433f7900452d14922ec9596f292a34df8daced67"},{"id":"s2","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41966639/","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","quote":"Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 ... ipamorelin, MOTS-C ... Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients.","summary":"2026 narrative review discussing ipamorelin among unapproved peptides, noting animal model benefits but scarce human safety data and regulatory concerns for sports medicine use.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"50f46187c788165037bbb94993c92d84e776164cc64d8a86d02b1c39d3264174"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"ipamorelin","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":2,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":2,"claims_total":2,"sources":2,"anecdotal":0,"scientific":2,"user_reports":0,"questions":0,"evidence_ingests":0}}